Celgene to look beyond Revlimid at R&D day

During Celgene's R&D day tomorrow--the first it has hosted in five years--the developer will attempt to show analysts that it has a promising drug pipeline beyond Revlimid, its top-selling multiple myeloma drug. Revlimid and its predecessor drug Thalomid accounted for almost 80 percent of the biotech's sales last year. Specifically, Reuters says Celgene will detail its programs for "lung cancer; chemotherapy-induced anemia; multiple myeloma; Crohn's disease, a gastrointestinal disorder; psoriasis, a skin disorder; and psoriatic arthritis."

Analysts are also waiting to see if Celgene will produce data supporting Revlimid as a maintenance treatment for multiple myeloma. That could boost the drug's sales from $1.7 billion in 2009 to $3.8 billion by 2013. The drug is also in clinical trials for chronic lymphocytic leukemia, non-Hodgkin's lymphoma, prostate cancer and colorectal cancer.

- read this item for more

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.